Please assess the completion status of the following clinical trial:

Trial Title: Phase III, Study of Three Short Course Combo (Ambisome®, Miltefosine, Paromomycin) Compared With AmBisome for the Treatment of VL in Bangladesh

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* VL proven by parasitological examination of splenic or bone marrow aspirate. Parasite burden to be graded according to Chulay and Bryceson 1983 and subsequently adopted by WHO. (Step 1 only)~* History of fever, for at least 2 weeks with one or more of the followings criteria: Anaemia (5\<Hb\<10g/dl), Loss of weight, Splenomegaly~* rk39 positive at baseline assessments~* willing and able to attend follow-up visits~* Male or Female age: 5-60 yrs~* Written informed consent from the patient or from patient's parent or guardian if the patient is under 18 yrs, in addition written assent from patients of 11 - 17 yrs of age. If the patient or parent/guardian are illiterate an impartial witness should be present during the consenting procedure and should also sign.~Exclusion Criteria:~* Married women of child-bearing potential (defined as women who have achieved menarche) who are not using an assured method of contraception or are unwilling to use an assured method of contraception for the duration of treatment and three months after. Assured methods of contraception include i.e. IUCD or depot hormone injection of medroxyprogesterone acetate MPA (DepoProvera®)~* Platelet count less than 40,000/mm3 (Step 1 only)~* Prothrombin time 5 seconds or greater than normal range (Step 1 only)~* Known hepatitis B, C or known HIV positive~* Patients who present with Para Kala-azar Dermal Leishmaniasis~* Signs/symptoms indicative of severe VL (Hb \< 5gm/dl, etc)~* Patients with a previous history of VL~* Patients who have received any investigational (unlicensed) drugs within the last 3 months~* Severe malnutrition BMI\<15 in adults, weight for height less than 60% in children~* Clinical symptoms of chronic underlying disease such as severe cardiac, renal or hepatic impairment~* Positive HRP2/pLDH Combo test for malaria~* Pregnant woman or breast-feeding mother~* Known alcohol or other drug abuse~* Concomitant chronic drug treatment eg. TB, HIV etc.~* Known hypersensitivity to AmBisome, Paromomycin and other aminoglycosides and/or Miltefosine

- Gender: ALL
- Minimum Age: 5 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Ambisome (Type: ACTIVE_COMPARATOR): 15mg Ambisome on days 1,3 and 5
- Ambisome + Miltefosine (Type: EXPERIMENTAL): Ambisome 5mg + miltefosine 10 days
- Ambisome +paromomycin (Type: EXPERIMENTAL): AmBisome IV infusion (single dose, day 1) + Paromomycin base 11mg/kg/day IM (Gland Pharma, India) for 10 days (days 2-11)
- Miltefosine + paromomycin (Type: EXPERIMENTAL): Oral Miltefosine 1.5-2.5 mg/kg in 1 or 2 doses a day, for 10 days (days 1-10) + Paromomycin base 11mg/kg/day IM for 10 days (days 1-10).

Based on this trial design, predict the completion outcome and termination type (if applicable).